psoriasis vulgaris
Conditions
Interventions
1%YXL Group :Topical application of 1% YXL ointment
5%YXL Group : Topical application of 5% YXL ointment
Positive drug Group:Topical application of 0.005% calcipotriene ointment
Sponsors
Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) Age range: from 18 to 75 years old, gender isn't limited. (2) Definitive diagnosis of mild or moderate plaque psoriasis vulgaris. a) Diagnosed with plaque psoriasis vulgaris at least half a year before the beginning of test, with the stable disease condition. b) The affected area of skin lesions of psoriasis vulgaris patients should be <=10% (excluding the scalp, groin area, and palmoplantar region) at the baseline examination, while the PGA score is 2 (mild) or 3 (moderate). (3) Female patients in child-bearing period are required to have the negative blood pregnancy test results and must agree to use effective and safe contraception throughout the study period. (4) Patients involved in the test should be with good compliance. (5) Patients involved in the test should sign the informed consent form voluntarily.
Exclusion criteria
Exclusion criteria: (1) Patients have been clearly diagnosed as guttate psoriasis vulgaris, erythrodermic psoriasis or pustular psoriasis. (2) Previous history of allergy and adverse reactions using Pleuromutilin drugs. (3) Patients have the drug history of oral or injected biological macromolecular drugs (such as adalimumab), retinoic acid drugs, immunosuppressants and other systemic drugs or topical using glucocorticoids, tretinoin drugs, calcineurin inhibitors and other drugs within 2 months. (4) Women who are in pregnant or breastfeeding period or unable to use effective contraception. (5) Patients have participated in other interventional clinical studies within 2 months. (6) Patients with mental disorders. (7) Patients with drug or alcohol addicts. (8) Other medical events are deemed inappropriate by the investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response rate of PGA; | — |
Secondary
| Measure | Time frame |
|---|---|
| Response rate of PASI75; | — |
Countries
China
Contacts
Public ContactYong Yang
Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College
Outcome results
None listed